What are the red flags for Pamela M. Sutton-Wallace?

AHA Dossiers Power Map About

Pamela M. Sutton-Wallace

Trustee, term 2026-2028

President & Acting CEO | Yale New Haven Health System

Last verified November 4, 2026

8 Red Flags

Affiliations

•Named Acting CEO of Yale New Haven Health System effective June 29, 2026, when CEO Christopher O'Connor left after 14 years; the board launched a national search, and no permanent CEO had been announced in public reporting as of November 4, 2026.
•President of Yale New Haven Health since early 2024, after serving as EVP and Chief Operating Officer from 2022.
•Group Senior Vice President and COO of the Weill Cornell division of NewYork-Presbyterian Hospital (2019-2022).
•CEO of University of Virginia Medical Center (2014-2019), after 17 years in progressive operating roles at Duke University Health System beginning in 1997.
•Independent director of Consensus Cloud Solutions (Nasdaq: CCSI), where she sits on the Audit Committee and chairs the ESG Committee; she was re-nominated for election at the June 10, 2026 annual meeting.
•MPH, Yale School of Public Health (1997); BA, Washington University in St. Louis.
•Elected to the AHA Board of Trustees for a three-year term that began January 1, 2026.

Financial / Compensation

•Her total compensation was $3,144,397 for fiscal 2025 as president of Yale New Haven Health, combined across the system's Form 990s, up from $1,672,126 reported for tax year 2023; her 2020 compensation at NewYork-Presbyterian was reported at $891,328.
•Schedule J breakdown (FY2025, Yale New Haven Health Services Corporation and five related returns): base salary $1.47M, bonus and incentive $1.02M, other reportable $13,527, retirement and deferred $633,153, nontaxable benefits $11,665; total $3.14M. Bonus and incentive pay was 32% of the total.
•Consensus Cloud Solutions paid her $270,004 in 2025 director compensation ($70,000 cash and $200,004 in stock), up from $217,525 in 2021.
•Yale New Haven Health posted a $197 million operating loss (-2.6% margin) for fiscal 2025, ended September 30, 2025, on $7.6 billion in operating revenue, versus a $46 million operating gain in fiscal 2024.
•The fiscal 2024 operating surplus of $46.2 million was driven largely by a one-time roughly $100 million 340B program settlement, meaning the system's core operations lost money for the fourth time in four years.
•Fiscal 2025 net income fell to $91 million from $411 million, and the system booked $57.7 million in restructuring expense, mainly severance and vendor contract terminations.
•S&P kept Yale New Haven Health at AA- in fall 2025 but revised the outlook to negative, citing operating losses and construction costs; Fitch affirmed its A+ rating in May 2025 after downgrading the system from AA- in June 2023.
•The system is building an $838 million neurosciences tower expected to open in 2027.
•Then-CEO O'Connor projected a $50 million surplus for fiscal 2026; Sutton-Wallace now owns delivery of that target as acting CEO.

Lobbying and Political

•Senate lobbying records show no 2025 or 2026 federal lobbying filed under Yale New Haven Health's own name; the system's federal advocacy runs largely through the AHA and the Connecticut Hospital Association.
•Yale New Haven Health is a dominant player in Connecticut's certificate-of-need process; state Sen. Ryan Fazio has said systems like it have the administrative, legal and lobbying capacity to manage CON that smaller rivals lack.
•A proposed independent proton therapy center in Danbury was denied through the CON process while Yale New Haven Health and Hartford HealthCare secured approval for their own joint proton facility in Wallingford.
•Connecticut's Office of Health Strategy approved the Prospect Medical hospital acquisition with conditions in March 2024 after a 16-month CON review; Yale New Haven Health then sued to exit the deal in late 2024.
•Broad CON reform collapsed in the final weeks of Connecticut's 2024 legislative session, preserving a framework that protects incumbents like Yale New Haven Health.

Revolving Door

•Career has run entirely through large academic medical systems (Duke, UVA, NewYork-Presbyterian, Yale New Haven), with early roles at Pfizer and Blue Cross Blue Shield of North Carolina.
•As UVA Medical Center CEO (2014-2019) she ran a state-owned academic hospital in Virginia.
•Holds a paid public-company board seat at Consensus Cloud Solutions, a health-information exchange and digital fax vendor, alongside her nonprofit executive role and AHA trusteeship.

Home System Record

•Yale New Haven Health's charity care at cost was $208M (latest hospital tax returns).
•Yale New Haven Health has 374 340B contract pharmacy arrangements registered with HRSA (OPAIS registry, Sept. 29, 2026).
•Yale New Haven Hospital was slated for about $90.4 million in federal 340B remedy payments for 2018-2022 underpayments, the fourth-largest amount nationally and the only Connecticut hospital in the top 100.
•In March 2025 the system announced an operating-model redesign that consolidated leadership; about 150 non-union Northeast Medical Group staff received layoff notices that month.
•A July 2025 voluntary retirement offer was accepted by about 600 employees; the system planned to rehire about 400, a net cut of roughly 200 positions, to save about $50 million.
•In October 2025 the CFO, general counsel, and Greenwich Hospital's COO and CFO departed, and a leadership restructuring affected about 38 management roles; a new CFO, Arnim Dontes, started April 1, 2026.
•In September 2025 Yale New Haven Health agreed to pay Prospect Medical Holdings $45 million to walk away from its $435 million agreement to buy Waterbury, Manchester Memorial and Rockville General hospitals; the bankruptcy court approved the deal.
•In July 2025 the system largely stopped gender-transition care for patients under 19.
•Rival Hartford HealthCare closed its $86.1 million purchase of Manchester Memorial and Rockville General on January 1, 2026, two of the three Prospect hospitals Yale New Haven Health had paid $45 million to walk away from.

Litigation and Scrutiny

•The $18 million class settlement over the March 2025 data breach, which affected about 5.3 to 5.6 million people, received final approval on March 3, 2026; up to $6 million is earmarked for attorneys' fees and claimant payments began May 27, 2026.
•The Prospect Medical purchase dispute ended with Yale New Haven Health's $45 million payment, approved in Prospect's Chapter 11 case in October 2025; it also resolved related litigation with landlord Medical Properties Trust.
•In December 2025, ten Connecticut families represented by GLAD Law sued Yale New Haven Health and Connecticut Children's, alleging the end of transgender care for minors violates Connecticut anti-discrimination law; the case is pending.
•In May 2023 Yale New Haven Health Services Corp. and Northeast Medical Group paid $560,718 to settle federal and state False Claims Act allegations covering July 2014 to June 2020 Bridgeport Hospital hospitalist billing; the whistleblower received $106,537.
•A long-running class action over Yale New Haven Hospital's treatment of uninsured patients, including inflated charges, liens and wage garnishment, remains part of the system's record, documented in the 2003 report Uncharitable Care.

Red Flags

She was handed the CEO job on an acting basis after the system lost $197 million from operations in fiscal 2025, and its only recent operating surplus was propped up by a one-time 340B windfall.

As President and COO since 2022 she ran the operations that produced operating losses in fiscal 2022, 2023 and 2025, yet her reported 990 pay reached about $1.67 million.

Yale New Haven Hospital collected the fourth-largest 340B remedy payment in the country, about $90.4 million, an outsized take for a dominant, investment-grade academic system.

The system paid $45 million, roughly 10% of the purchase price, to escape a hospital acquisition it had spent 16 months lobbying regulators to approve, leaving three community hospitals to a bankruptcy auction.

The 2025 data breach exposed 5.3 to 5.6 million patient records and ended in an $18 million settlement where up to a third goes to lawyers.

S&P's negative outlook and an $838 million tower under construction put a debt-financed expansion on a balance sheet that is losing money from operations.

She collects a public-company director package of $270,004 a year from a health-IT vendor while running a nonprofit system and sitting on the AHA board.

Yale New Haven Health's CON advantages, including the Danbury proton denial, show the system using state entry barriers that the AHA defends to block lower-cost competitors.

Pattern Summary

Sutton-Wallace is a career academic-medical-center operator who rose to acting CEO of Connecticut's dominant hospital system in June 2026 amid operating losses, executive purges, a failed acquisition and a mass data breach. Her system's recent surplus came from a 340B settlement, not operations, and it wields Connecticut's CON regime to wall off competitors. Her AHA seat puts a leader whose system depends on 340B money and entry barriers in a position to steer the lobby defending both.

Pamela M. Sutton-Wallace

Red Flags

Sources and Citations